المؤلفون: Gennaro Pagano (291011), Frank G. Boess (11512171), Kirsten I. Taylor (11512174), Benedicte Ricci (11512177), Brit Mollenhauer (482499), Werner Poewe (213925), Anne Boulay (11512180), Judith Anzures-Cabrera (11512183), Annamarie Vogt (11512186), Maddalena Marchesi (310644), Anke Post (11512189), Tania Nikolcheva (239801), Gene G. Kinney (11512192), Wagner M. Zago (11512195), Daniel K. Ness (2126917), Hanno Svoboda (271649), Markus Britschgi (10077109), Susanne Ostrowitzki (4673434), Tanya Simuni (4030655), Kenneth Marek (4102666), Martin Koller (1554103), Jeff Sevigny (11512198), Rachelle Doody (337956), Paulo Fontoura (4673440), Daniel Umbricht (9162722), Azad Bonni (221908), PASADENA Investigators (11512201), Prasinezumab Study Group (11512204)

مصطلحات موضوعية: Neurology and Neuromuscular Diseases, Neurogenetics, Parkinson's disease, alpha-synuclein (α-syn), prasinezumab, monoclonal antibodies, disease progression, MDS-UPDRS = Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Phase II clinical trial, disease modification treatments

Relation: https://figshare.com/articles/dataset/Data_Sheet_1_A_Phase_II_Study_to_Evaluate_the_Safety_and_Efficacy_of_Prasinezumab_in_Early_Parkinson_s_Disease_PASADENA_Rationale_Design_and_Baseline_Data_docx/16722577

الاتاحة: https://doi.org/10.3389/fneur.2021.705407.s001